Wellington Management Group
AXSM icon

Wellington Management Group’s Axsome Therapeutics AXSM Stock Holding History

Wellington Management Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$194M Sell
1,145,306
-76,350
-6% -$13.2M 0.04% 388
2025
Q4 		$223M Sell
1,221,656
-112,904
-8% -$15.8M 0.04% 360
2025
Q3 		$162M Buy
1,334,560
+609,516
+84% +$68.7M 0.03% 434
2025
Q2 		$75.7M Buy
725,044
+21,765
+3% +$2.3M 0.01% 597
2025
Q1 		$82M Buy
703,279
+30,122
+4% +$3.43M 0.02% 558
2024
Q4 		$57M Sell
673,157
-69,588
-9% -$6.4M 0.01% 674
2024
Q3 		$66.8M Buy
742,745
+8,125
+1% +$709K 0.01% 637
2024
Q2 		$59.1M Buy
734,620
+57,974
+9% +$4.29M 0.01% 661
2024
Q1 		$54M Buy
676,646
+436,827
+182% +$36.7M 0.01% 689
2023
Q4 		$19.1M Buy
239,819
+2,265
+1% +$151K ﹤0.01% 951
2023
Q3 		$16.6M Buy
237,554
+37,843
+19% +$2.83M ﹤0.01% 974
2023
Q2 		$14.4M Buy
+199,711
New +$14.7M ﹤0.01% 1022

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Wellington Management Group's AXSM Position: Q1 2026 in Review

Wellington Management Group reduced its Axsome Therapeutics (AXSM) stake by 6.2% in Q1 2026, selling an estimated $13.2M and leaving 1,145,306 shares worth $194M. The position accounts for 0.04% of the portfolio, ranked #388.

Wellington Management Group first reported a position in AXSM in Q2 2023 and has held it in 12 quarters since. The position peaked at $223M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Wellington Management Group held 1,145,306 shares of Axsome Therapeutics worth $194M as of Q1 2026.
  • Wellington Management Group sold 76,350 Axsome Therapeutics shares in Q1 2026, an estimated $13.2M.
  • Axsome Therapeutics made up 0.04% of Wellington Management Group's portfolio in Q1 2026, its #388 holding.
  • Wellington Management Group first reported a position in Axsome Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • Wellington Management Group's Axsome Therapeutics position peaked at $223M in Q4 2025.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Wellington Management Group's 13F filing for Q1 2026, filed 15 May 2026.